NEW YORK--(BUSINESS WIRE)--Regulatory News:
Cellectis (Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on the development of gene edited, next generation CAR T-cell product candidates for the treatment of cancer, today announced presentations at the following upcoming banking conferences and events:
Help employers find you! Check out all the jobs and post your resume.
